X

Publications

Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy

Mavroudis PD1, van den Anker J2,3, Conklin LS2,3, Damsker JM2, Hoffman EP2,4, Nagaraju K2,4, Clemens PR5, Jusko WJ1.

Link to full article >

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy

Heier CR1,2, Yu Q2, Fiorillo AA3,2, Tully CB2, Tucker A2, Mazala DA2, Uaesoontrachoon K4, Srinivassane S4, Damsker JM5, Hoffman EP4,5,6, Nagaraju K4,5,6, Spurney CF3,2,7.

Link to full article >

Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset

Damsker JM1, Cornish MR2, Kanneboyina P2, Kanneboyina I2, Yu Q3, Lipson R2, Phadke A3, Knoblach SM3, Panchapakesan K3, Morales M4, Fiorillo AA3, Partridge T3, Nagaraju K5,6,7.

Link to full article >

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement in muscle function

Hoffman EP1, Schwartz BD2, Mengle-Gaw LJ2, Smith EC2, Castro D2, Mah JK2, McDonald CM2, Kuntz NL2, Finkel RS2, Guglieri M2, Bushby K2, Tulinius M2, Nevo Y2, Ryan MM2, Webster R2, Smith AL2, Morgenroth LP2, Arrieta A2, Shimony M2, Siener C2, Jaros M2, Shale P2, McCall JM2, Nagaraju K2, van den Anker J2, Conklin LS2, Cnaan A2, Gordish-Dressman H2, Damsker JM2, Clemens PR2; Cooperative International Neuromuscular Research Group.

Link to full article >

Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone

Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR.

Physiol Genomics. 2018 Sep 1;50(9):735-745. PMID: 29883261
Link to full article >

Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.

Akkad H, Cacciani N, Llano-Diez M, Corpeno Kalamgi R, Tchkonia T, Kirkland JL, Larsson L.

Acta Physiol (Oxf). 2018 Aug 18:e13172. PMID: 30120816
Link to full article >

Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit

Sreetama SC, Chandra G, Van der Meulen JH, Ahmad MM, Suzuki P, Bhuvanendran S, Nagaraju K, Hoffman EP, Jaiswal JK.

Mol Ther. 2018 Sep 5;26(9):2231-2242. PMID: 30166241
Link to full article >

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR.

Pharmacol Res. 2018 Sep 13;136:140-150.
Link to full article >

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes

Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonia M, Kramer WG, et al. Steroids. 2018; 134: 43-52
Link to full article >

Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone

Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR. Physiol Genomics. 2018.
Link to full article >